847650-91-3

Basic information

• Product Name: 1-((2R,4S,5R)-3,4-anhydro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-4(1H)-one
• Synonyms: 1-((2R,4S,5R)-3,4-anhydro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-4(1H)-one
• CAS NO: 847650-91-3
• Molecular Weight: 226.189
• Mol File: 847650-91-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-((2R,4S,5R)-3,4-anhydro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-4(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-((2R,4S,5R)-3,4-anhydro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-4(1H)-one(847650-91-3)
• EPA Substance Registry System: 1-((2R,4S,5R)-3,4-anhydro-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-4(1H)-one(847650-91-3)

Safety Data

• Hazardous Substances Data: 847650-91-3(Hazardous Substances Data)

Upstream product

• 58-96-8 uridine 
• 54618-06-3 5′-O-benzoyluridine 

Downstream Products

• 2140-76-3 2'-O-methyluridine 
• 251647-51-5 5’-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2’-O-(2-methoxyethyl)uridine 
• 3083-77-0 araU 

Relevant articles and documents

ANTISENSE OLIGONUCLEOTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES

The invention relates to an antisense or siRNA oligonucleotide or conjugate with improved pharmacokinetic properties, methods of producing the same as well as the use of such compounds and conjugates, e.g. as pharmaceutical composition, a pharmaceutical kit, a medicament or a tool in biomedical research. The conjugates of the invention have the formula I being P - (L - S - S - Y - X)n, wherein P represents a natural, artificial and/or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence; S represents sulfur; X represents a ligand; Y represents a spacer and n is an integer ranging from 1 to the oligonucleotide length of P. The oligonucleotides of the invention have the formula II being P- (L - S - R)n, wherein P represents a natural, artificial and /or modified oligonucleotide, L represents a linker group attached to one or more nucleosides at any position within the oligonucleotides sequence, S represents sulfur, R represents either hydrogen or a thiol protecting group, preferably trityl or tertiary butyl, and n is an integer ranging from 1 to the oligonucleotide length of P. In addition, the pharmaceutical composition or pharmaceutical kit or conjugate can be used for the treatment of a disease or disorder that can be at least in part alleviated by therapy, wherein the disease or disorder is selected from the group consisting of bacterial infections, viral infections, cancer, metabolic diseases and immunological disorders and preferably cancer.

2′-O-dimethylaminoethoxyuridine and 5-dimethylaminopropargyl deoxyuridine for at base pair recognition in triple helices

The nucleoside analogues 2′-O-dimethylaminoethoxy uridine and 5-dimethylaminopropargyl deoxyuridine have been synthesised and incorporated into oligonucleotides. Their triplex-stabilising properties have been determined in fluorescence melting experiments